A compound of Formula (Ie), or a stereoisomer, racemate, geometric isomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, wherein, X 1 is selected from the group consisting of CH, CD and N; R 1 is selected from the group consisting of H and D; R 2 is selected from the group consisting of C 1-6 alkyl optionally substituted with one or more hydroxyl, C 3-8 cycloalkyl optionally substituted with one or more hydroxyl, 3-8 membered heterocyclyl, and 5-12 membered heteroaryl such as 5-7 membered heteroaryl optionally substituted with one or more substituents selected from -CD 3, C 1-6 alkyl and hydroxylC 1-6 alkyl; R 3 is selected from the group consisting of halo and C 1-6 alkyl; R 4 is -CO(CR 10 R 11) m R 12, wherein m is 0, 1, 2 or 3, and wherein R 10 and R 11 are each independently selected from the group consisting of H, D, and C 1-4 alkyl optionally substituted with hydroxyl; and R 12 is selected from the group consisting of optionally substituted phenyl and optionally substituted pyridinyl such as pyridin-3-yl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C 1-4 alkyl (for example, methyl or ethyl), cyano, and C 3-8 heterocyclyl-(CH 2) 0-4 - (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl); and R 5, R 6, R 7 and R 8 are each independently selected from the group consisting of H and C 1-6 alkyl optionally substituted with hydroxyl or -OC 1 -C 6 alkyl, provided that the compound is not 2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(hydroxylmethyl)-5-(2-(isopropylamino)pyrimidin-4-y l)indolin-1-yl)ethan-1-one. X 1 is selected from the group consisting of CH, CD and N; R 1 is selected from the group consisting of H and D; R 2 is selected from the group consisting of C 1-6 alkyl optionally substituted with one or more hydroxyl, C 3-8 cycloalkyl optionally substituted with one or more hydroxyl, 3-8 membered heterocyclyl, and 5-12 membered heteroaryl such as 5-7 membered heteroaryl optionally substituted with one or more substituents selected from -CD 3, C 1-6 alkyl and hydroxylC 1-6 alkyl; R 3 is selected from the group consisting of halo and C 1-6 alkyl; R 4 is -CO(CR 10 R 11) m R 12, wherein m is 0, 1, 2 or 3, and wherein R 10 and R 11 are each independently selected from the group consisting of H, D, and C 1-4 alkyl optionally substituted with hydroxyl; and R 12 is selected from the group consisting of optionally substituted phenyl and optionally substituted pyridinyl such as pyridin-3-yl, wherein the optional substituent is one or more substituents independently selected from the group consisting of D, halo, C 1-4 alkyl (for example, methyl or ethyl), cyano, and C 3-8 heterocyclyl-(CH 2) 0-4 - (for example, morpholinyl such as morpholino, piperazinyl, tetrahydropyranyl such as tetrahydropyran-4-yl, morpholinylmethyl such as morpholinomethyl, or piperazinylmethyl); and R 5, R 6, R 7 and R 8 are each independently selected from the group consisting of H and C 1-6 alkyl optionally substituted with hydroxyl or -OC 1 -C 6 alkyl, provided that the compound is not 2-(2-chloropyridin-3-yl)-1-(7-fluoro-2-(hydroxylmethyl)-5-(2-(isopropylamino)pyrimidin-4-y l)indolin-1-yl)ethan-1-one.